|
TABLE
OF CONTENTS
OVERVIEW OF MAJOR SURVEY FINDINGS
i.
Respondent Profiles
ii.
Benign Prostate Disorder Management
iii.
Female Urinary Incontinence Management
iv.
Prostate Cancer Management
v.
Erectile Dysfunction Management
vi.
Developments Impacting Urologic Practice
1. RESPONDENT PROFILES
1.1
Survey Respondents
1.1.1 Respondents, By Age Group
1.1.2 Respondents, By Region
1.1.3 Respondents, by Practice Type
1.1.4 Respondents, by Practice Ownership
1.1.5 Respondents, by Patient Volumes and Caseload Groups
1.1.6 Respondents, by Practice Distribution
2. BENIGN PROSTATE DISORDER MANAGEMENT
2.1
Benign Prostatic Hyperplasia Symptoms at Presentation
2.2
Effectiveness of Benign Prostatic Hyperplasia Treatments
2.3
Familiarity with Benign Prostatic Hyperplasia Treatments
2.4
Current and Planned Use of Emerging Benign Prostatic Hyperplasia
Therapies
2.4.1 Current and Planned Use of Transurethral Microwave
Thermal
Therapy
2.4.2 Current and Planned Use of Transurethral
Radiofrequency Needle
Ablation
2.4.3 Current and Planned Use of Holmium Laser Resection of
the
Prostate
2.4.4 Current and Planned Use of Photoselective
Vaporization of the
Prostate
2.4.5 Other Benign Prostatic Hyperplasia Therapies
2.5
Obstacles to Expanded Use of Minimally Invasive Benign Prostatic
Hyperplasia
Therapies
2.6
Potential Clinical Value of Short-Term Urethral Stents
2.7
Prostatitis Symptoms and Management
3. FEMALE URINARY INCONTINENCE MANAGEMENT
3.1
Obstacles to the Widespread Treatment of Female Urinary
Incontinence
3.2
Urinary Incontinence Treatments
3.2.1 Effectiveness of Urinary Incontinence Treatments
3.2.2 Familiarity with Urinary Incontinence Treatments
3.2.3 Current and Planned Use of Urinary Incontinence
Treatments
3.3
Urodynamics Equipment
3.3.1 Current and Planned Urodynamics Equipment Ownership
4. PROSTATE CANCER MANAGEMENT
4.1
First-Year Treatment Protocols
4.2
Challenges Associated with Prostate Cancer Management
4.3
Transrectal Ultrasound Equipment
4.3.1 Current and
Planned Transrectal Ultrasound Equipment Ownership
5. ERECTILE DYSFUNCTION MANAGEMENT
5.1
Effectiveness of Erectile Dysfunction Treatments
5.2
Familiarity with Erectile Dysfunction Treatments
5.3
Current and Planned Use of Erectile Dysfunction Treatments
5.4
Types of Patients Treated with Oral Erectile Dysfunction Drugs
6. DEVELOPMENTS IMPACTING UROLOGIC PRACTICE
6.1
Important Developments in Urologic Practice
6.2
Selected Companies Serving the Urology Products Market
6.2.1 American Medical Systems
6.2.2 C.R. Bard
6.2.3 Boston Scientific
6.2.4 Circon
6.2.5 Cook
6.2.6 Johnson & Johnson
6.2.7 Mentor
6.2.8 Karl Storz
6.2.9 Timm Medical Technologies
6.2.10 Urologix
COMPANY LISTING
LIST OF EXHIBITS
Exhibit 1-1:
Distribution of the General United States Urologist
Population and
Survey Respondents, by Age Group
Exhibit 1-2: Distribution
of the General United States Urologist Population and
Survey Respondents, by Geographic Region
Exhibit 1-3: Survey
Respondents, by Practice Type
Exhibit 1-4: Survey
Respondents, by Age Group and Practice Type
Exhibit 1-5: Distribution
of Survey Respondents, by Practice Ownership
Exhibit 1-6: Weekly
Patient Volumes, All Survey Respondents
Exhibit 1-7: Weekly
Patient Volumes, by Survey Respondent Age
Exhibit 1-8: Weekly
Patient Volumes, by Practice Type
Exhibit 1-9: Distribution
of Survey Respondents, by Patient Caseload Group
Exhibit 1-10: Distribution
of Survey Respondents, by Respondent Age and Patient Caseload
Group
Exhibit 1-11: Distribution
of Survey Respondents, by Practice Type and Patient
Caseload Group
Exhibit 1-12: Average
Practice Distribution, All Respondents
Exhibit 1-13: 2001,
Average Practice Distribution, By Respondent Age
Exhibit 1-14: 2001,
Average Practice Distribution, by Practice Type
Exhibit 1-15: 2001,
Average Practice Distribution, By Patient Volumes
Exhibit 1-16: 2001,
Average Practice Distribution, by Geographical Region
Exhibit 2-1:
Severity of Patients’ Benign Prostatic Hyperplasia
Symptoms at
Initial Presentation, All Survey Respondents
Exhibit 2-2:
Severity of Patients’ Benign Prostatic Hyperplasia
Symptoms at
Initial Presentation, by Survey Respondent Age Group
Exhibit 2-3:
Severity of Patients’ Benign Prostatic Hyperplasia
Symptoms at
Initial Presentation, by Practice Type
Exhibit 2-4:
Severity of Patients’ Benign Prostatic Hyperplasia
Symptoms at
Initial Presentation, by Patient Volumes
Exhibit 2-5:
Severity of Patients’ Benign Prostatic Hyperplasia
Symptoms at
Initial Presentation, by Geographical Region
Exhibit 2-6:
Rated Effectiveness of Benign Prostatic Hyperplasia
Therapies, All
Survey Respondents
Exhibit 2-7:
Rated Effectiveness of Benign Prostatic Hyperplasia
Therapies, by
Survey Respondent Age Group
Exhibit 2-8:
Rated Effectiveness of Benign Prostatic Hyperplasia
Therapies, by
Practice Type
Exhibit 2-9:
Rated Effectiveness of Benign Prostatic Hyperplasia
Therapies, by
Patient Volumes
Exhibit 2-10: Rated
Effectiveness of Benign Prostatic Hyperplasia Therapies, by
Geographical Region
Exhibit 2-11: Shares
of Urologists Not Familiar with Emerging Benign Prostatic
Hyperplasia Therapies, All Survey Respondents
Exhibit 2-12: Shares
of Urologists Not Familiar with Emerging Benign Prostatic
Hyperplasia Therapies, by Survey Respondent Age Group
Exhibit 2-13: Shares
of Urologists Not Familiar with Emerging Benign Prostatic
Hyperplasia Therapies, by Practice Type
Exhibit 2-14: Shares
of Urologists Not Familiar with Emerging Benign Prostatic
Hyperplasia Therapies, by Patient Volumes
Exhibit 2-15: Shares
of Urologists Not Familiar with Emerging Benign Prostatic
Hyperplasia Therapies, by Geographical Region
Exhibit 2-16: Current
and Planned Use of Emerging Benign Prostatic
Hyperplasia Therapies, All Survey Respondents
Exhibit 2-17: Current
and Planned Use of Transurethral Microwave Thermal
Therapy, by Survey Respondent Age Group, Practice Type,
Patient Volumes, and Geographical Region
Exhibit 2-18: Current
and Planned Use of Transurethral Radiofrequency Needle
Ablation, by Survey Respondent Age Group, Practice Type,
Patient Volumes, and Geographical Region
Exhibit 2-19: Current
and Planned Use of Holmium Laser Resection of the
Prostate, by Survey Respondent Age Group, Practice Type,
Patient Volumes, and Geographical Region
Exhibit 2-20: Current
and Planned Use of Photoselective Vaporization of the
Prostate, by Survey Respondent Age Group, Practice Type,
Patient Volumes, and Geographical Region
Exhibit 2-21: Obstacles
to Widespread Adoption of Minimally Invasive Therapies
for Benign Prostatic Hyperplasia, All Survey Respondents
Exhibit 2-22: Factors
Rated “Major Obstacle” to the Adoption of Minimally
Invasive Benign Prostatic Hyperplasia Treatments, by Survey
Respondent Age Group
Exhibit 2-23: Factors
Rated “Major Obstacle” to the Adoption of Minimally
Invasive Benign Prostatic Hyperplasia Treatments, by Practice
Type
Exhibit 2-24: Factors
Rated “Major Obstacle” to the Adoption of Minimally
Invasive Benign Prostatic Hyperplasia Treatments, by Patient
Volumes
Exhibit 2-25: Factors
Rated “Major Obstacle” to the Adoption of Minimally
Invasive Benign Prostatic Hyperplasia Treatments, by Geographical
Region
Exhibit 2-26: Potential
Clinical Value of Short-Term Urethral Stents Within the
Urology Practice, All Survey Respondents
Exhibit 2-27: Potential
Clinical Value of Short-Term Urethral Stents Within the
Urology Practice, by Survey Respondent Age Group
Exhibit 2-28: Potential
Clinical Value of Urethral Stents Within the Urology
Practice, by Practice Type
Exhibit 2-29: Potential
Clinical Value of Urethral Stents Within the Urology
Practice, by Patient Volumes
Exhibit 2-30: Potential
Clinical Value of Urethral Stents Within the Urology
Practice, by Geographical Region
Exhibit 2-31: Prostatitis
Patients’ Symptoms, All Survey Respondents
Exhibit 2-32: Prostatitis
Patients’ Symptoms, by Survey Respondent Age Group
Exhibit 2-33: Prostatitis
Patients’ Symptoms, by Practice Type
Exhibit 2-34: Prostatitis
Patients’ Symptoms, by Patient Volumes
Exhibit 2-35: Prostatitis
Patients’ Symptoms, by Geographical Region
Exhibit 3-1:
Obstacles to the Widespread Treatment of Female Urinary
Incontinence by Urologists, All Survey Respondents
Exhibit 3-2:
Factors Rated “Major Obstacle” to the Widespread
Treatment of
Female Urinary Incontinence by Urologists, by Survey Respondent
Age Group
Exhibit 3-3:
Factors Rated “Major Obstacle” to the Widespread
Treatment of
Female Urinary Incontinence by Urologists, by Practice Type
Exhibit 3-4:
Factors Rated “Major Obstacle” to the Widespread
Treatment of
Female Urinary Incontinence by Urologists, by Patient Volumes
Exhibit 3-5:
Factors Rated “Major Obstacle” to the Widespread
Treatment of
Female Urinary Incontinence by Urologists, by Geographical
Region
Exhibit 3-6:
Rated Effectiveness of Urinary Incontinence Treatments, All
Survey Respondents
Exhibit 3-7:
Rated Effectiveness of Urinary Incontinence Treatments, by
Survey Respondent Age Group
Exhibit 3-8:
Rated Effectiveness of Urinary Incontinence Treatments, by
Practice Type
Exhibit 3-9:
Rated Effectiveness of Urinary Incontinence Treatments, by
Patient Volumes
Exhibit 3-10: Rated
Effectiveness of Urinary Incontinence Treatments, by
Geographical Region
Exhibit 3-11: Shares
of Urologists Not Familiar with Urinary Incontinence
Treatments, All Survey Respondents
Exhibit 3-12: Shares
of Urologists Not Familiar with Urinary Incontinence
Treatments, by Survey Respondent Age Group
Exhibit 3-13: Shares
of Urologists Not Familiar with Urinary Incontinence
Treatments, by Practice Type
Exhibit 3-14: Shares
of Urologists Not Familiar with Urinary Incontinence
Treatments, by Patient Volumes
Exhibit 3-15: Shares
of Urologists Not Familiar with Urinary Incontinence
Treatments, by Geographical Region
Exhibit 3-16: Current
and Planned Use of Urinary Incontinence Treatments, All
Survey Respondents
Exhibit 3-17: Current
and Planned Use of Major Urinary Incontinence Surgery,
by Survey Respondent Age Group, Practice Type, Patient
Volumes, and Geographical Region
Exhibit 3-18: Current
and Planned Use of Minimally Invasive Urinary
Incontinence Surgery, by Survey Respondent Age Group, Practice
Type, Patient Volumes, and Geographical Region
Exhibit 3-19: Current
and Planned Use of Resorbable Bulking Agents, by Survey
Respondent Age Group, Practice Type, Patient Volumes, and
Geographical Region
Exhibit 3-20: Current
and Planned Use of Nonresorbable Bulking Agents, by
Survey Respondent Age Group, Practice Type, Patient Volumes,
and Geographical Region
Exhibit 3-21: Current
and Planned Use of Radiofrequency Bladder Neck
Suspension, by Survey Respondent Age Group, Practice Type,
Patient Volumes, and Geographical Region
Exhibit 3-22: Current
and Planned Use of Extracorporeal Magnetic Innervation,
by Survey Respondent Age Group, Practice Type, Patient
Volumes, and Geographical Region
Exhibit 3-23: Current
and Planned Ownership of Urodynamics Equipment, All
Survey Respondents
Exhibit 3-24: Current
and Planned Ownership of Urodynamics Equipment, by
Survey Respondent Age Group
Exhibit 3-25: Current
and Planned Ownership of Urodynamics Equipment, by
Practice Type
Exhibit 3-26: Current
and Planned Ownership of Urodynamics Equipment, by
Patient Volumes
Exhibit 3-27: Current
and Planned Ownership of Urodynamics Equipment, by
Geographical Region
Exhibit 3-28: Urodynamics
Systems that Survey Respondents Currently Own or
Plan to Purchase, by Manufacturer
Exhibit 4-1:
Distribution of Prostate Cancer Patients by Treatment
Modality for
the Years 2001 and 2003, All Survey Respondents
Exhibit 4-2:
Distribution of Prostate Cancer Patients by Treatment
Modality for
the Years 2001 and 2003, by Survey Respondent Age Group
Exhibit 4-3:
Distribution of Prostate Cancer Patients by Treatment
Modality for
the Years 2001 and 2003, by Practice Type
Exhibit 4-4:
Distribution of Prostate Cancer Patients by Treatment
Modality for
the Years 2001 and 2003, by Patient Volumes
Exhibit 4-5:
Distribution of Prostate Cancer Patients by Treatment
Modality for
the Years 2001 and 2003, by Geographical Region
Exhibit 4-6:
Challenges Associated with Prostate Cancer Management, All
Survey Respondents
Exhibit 4-7:
Factors Rated “Major Challenge” or “Moderate
Challenge” to the
Treatment of Prostate Cancer, by Survey Respondent Age Group
Exhibit 4-8:
Factors Rated “Major Challenge” or “Moderate
Challenge” to the
Treatment of Prostate Cancer, by Practice Type
Exhibit 4-9:
Factors Rated “Major Challenge” or “Moderate
Challenge” to the
Treatment of Prostate Cancer, by Patient Volumes
Exhibit 4-10: Factors
Rated “Major Challenge” or “Moderate Challenge” to the
Treatment of Prostate Cancer, by Geographical Region
Exhibit 4-11: Current
and Planned Ownership of Transrectal Ultrasound
Equipment, All Survey Respondents
Exhibit 4-12: Current
and Planned Ownership of Transrectal Ultrasound
Equipment, by Survey Respondent Age Group
Exhibit 4-13: Current
and Planned Ownership of Transrectal Ultrasound
Equipment, by Practice Type
Exhibit 4-14: Current
and Planned Ownership of Transrectal Ultrasound
Equipment, by Patient Volumes
Exhibit 4-15: Current
and Planned Ownership of Transrectal Ultrasound
Equipment, by Geographical Region
Exhibit 4-16: Transrectal
Ultrasound Equipment Mentions, All Survey
Respondents
Exhibit 4-17: Transrectal
Ultrasound Equipment Manufacturer Mentions, by
Survey Respondent Age Group
Exhibit 4-18: Transrectal
Ultrasound Equipment Manufacturer Mentions, by
Survey Respondent Practice Type
Exhibit 4-19: Transrectal
Ultrasound Equipment Manufacturer Mentions, by
Survey Respondent Patient Volumes
Exhibit 4-20: Transrectal
Ultrasound Equipment Manufacturer Mentions, by
Geographical Region
Exhibit 5-1:
Rated Effectiveness of Erectile Dysfunction Treatments, All
Survey Respondents
Exhibit 5-2:
Rated Effectiveness of Erectile Dysfunction Treatments, by
Survey Respondent Age Group
Exhibit 5-3:
Rated Effectiveness of Erectile Dysfunction Treatments, by
Practice Type
Exhibit 5-4:
Rated Effectiveness of Erectile Dysfunction Treatments, by
Patient Volumes
Exhibit 5-5:
Rated Effectiveness of Erectile Dysfunction Treatments, by
Geographical Region
Exhibit 5-6:
Shares of Urologists Not Familiar with Erectile Dysfunction
Treatments, All Survey Respondents
Exhibit 5-7:
Shares of Urologists Not Familiar with Erectile Dysfunction
Treatments, by Survey Respondent Age Group
Exhibit 5-8:
Shares of Urologists Not Familiar with Erectile Dysfunction
Treatments, by Practice Type
Exhibit 5-9:
Shares of Urologists Not Familiar with Erectile Dysfunction
Treatments, by Patient Volumes
Exhibit 5-10: Shares
of Urologists Not Familiar with Erectile Dysfunction
Treatments, by Geographical Region
Exhibit 5-11: Current
and Planned Use of Erectile Dysfunction Treatments, All
Survey Respondents
Exhibit 5-12: Current
and Planned Use of Topical Alprostadil Formulations, by
Survey Respondent Age Group, Practice Type, Patient Volumes,
and Geographical Region
Exhibit 5-13: Current
and Planned Use of Cialis, by Survey Respondent Age
Group, Practice Type, Patient Volumes, and Geographical Region
Exhibit 5-14: Current
and Planned Use of Vardenafil, by Survey Respondent
Age Group, Practice Type, Patient Volumes, and Geographical
Region
Exhibit 5-15: Types
of Patients Treated with Oral Erectile Dysfunction Drugs for
the Years 2001 and 2003, All Survey Respondents
Exhibit 5-16: Shares
of Patients Treated with Oral Erectile Dysfunction Drugs to
Improve/Enhance Sexual Performance for the Years 2001 and
2003, by Survey Respondent Age Group, Practice Type, Patient
Volumes, and Geographical Region
Exhibit 6-1:
Developments Expected to Have the Greatest Impact on
Urologic
Practice Over the Next Two to Three Years, All Survey
Respondents
Exhibit 6-2:
Urology Device Manufacturer Ratings, All Survey Respondents
Exhibit 6-3:
Shares of Survey Respondents Not Familiar with Selected
Urology
Device Manufacturers
Exhibit 6-4:
Ratings for American Medical Systems, by Survey
Respondent
Age Group, Practice Type, Patient Volumes, and Geographical
Region
Exhibit 6-5:
Lack of Familiarity with American Medical Systems, by
Survey
Respondent Age Group, Practice Type, Patient Volumes, and
Geographical Region
Exhibit 6-6:
Ratings for C.R. Bard, by Survey Respondent Age Group,
Practice
Type, Patient Volumes, and Geographical Region
Exhibit 6-7:
Lack of Familiarity with C.R. Bard, by Survey Respondent
Age
Group, Practice Type, Patient Volumes, and Geographical Region
Exhibit 6-8:
Ratings for Boston Scientific, by Survey Respondent Age
Group,
Practice Type, Patient Volumes, and Geographical Region
Exhibit 6-9:
Lack of Familiarity with Boston Scientific, by Survey
Respondent
Age Group, Practice Type, Patient Volumes, and Geographical
Region
Exhibit 6-10: Ratings
for Circon, by Survey Respondent Age Group, Practice
Type, Patient Volumes, and Geographical Region
Exhibit 6-11: Lack
of Familiarity with Circon, by Survey Respondent Age Group,
Practice Type, Patient Volumes, and Geographical Region
Exhibit 6-12: Ratings
for Cook, by Survey Respondent Age Group, Practice
Type, Patient Volumes, and Geographical Region
Exhibit 6-13: Lack
of Familiarity with Cook, by Survey Respondent Age Group,
Practice Type, Patient Volumes, and Geographical Region
Exhibit 6-14: Ratings
for Johnson & Johnson, by Survey Respondent Age Group,
Practice Type, Patient Volumes, and Geographical Region
Exhibit 6-15: Lack
of Familiarity with Johnson & Johnson, by Survey
Respondent Age Group, Practice Type, Patient Volumes, and
Geographical Region
Exhibit 6-16: Ratings
for Mentor, by Survey Respondent Age Group, Practice
Type, Patient Volumes, and Geographical Region
Exhibit 6-17: Lack
of Familiarity with Mentor, by Survey Respondent Age
Group, Practice Type, Patient Volumes, and Geographical Region
Exhibit 6-18: Ratings
for Karl Storz, by Survey Respondent Age Group, Practice
Type, Patient Volumes, and Geographical Region
Exhibit 6-19: Lack
of Familiarity with Karl Storz, by Survey Respondent Age
Group, Practice Type, Patient Volumes, and Geographical Region
Exhibit 6-20: Ratings
for Timm Medical Technologies, by Survey Respondent
Age Group, Practice Type, Patient Volumes, and Geographical
Region
Exhibit 6-21: Lack
of Familiarity with Timm Medical Technologies, by Survey
Respondent Age Group, Practice Type, Patient Volumes, and
Geographical Region
Exhibit 6-22: Ratings
for Urologix, by Survey Respondent Age Group, Practice
Type, Patient Volumes, and Geographical Region
Exhibit 6-23: Lack
of Familiarity with Urologix, by Survey Respondent Age
Group, Practice Type, Patient Volumes, and Geographical Region |
